Aptorum Group Limited
APM.PA
Euronext Paris3.21
EUR
- -
- -
Aptorum Group Limited
APM.PA
(Euronext Paris)
Recent
price
3.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM.PA) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets targeting unmet medical needs in oncology including orphan oncology indications, infectious diseases, neurological disorders and metabolic diseases; its lead product candidates include the ALS-4 platform for neurological disorders, SACT-1 for oncology, RPIDD for infectious diseases, and NLS-1 for metabolic conditions, complemented by precision diagnostic technologies and computational drug discovery through its Smart Pharma subsidiary. Founded in 2010 and headquartered in London, United Kingdom, the company operates globally with research and development activities spanning the United Kingdom, Hong Kong and other regions, serving clients worldwide through its therapeutics and healthcare services segments. In recent developments, Aptorum Group completed a $2 million registered direct offering in October 2025 to fund working capital and expenses related to its proposed merger with DiamiR Biosciences Corp., under which DiamiR shareholders would own approximately 70% of the combined entity pending shareholder approval and customary conditions; the company also filed a Form F-1 in November 2025 to register shares for resale by selling securityholders and conducted prior financings including a January 2025 share sale.